NEUROCRINE BIOSCIENCES INC (1NBIX.MI) Fundamental Analysis & Valuation

BIT:1NBIX • US64125C1099

Current stock price

113 EUR
+1.45 (+1.3%)
Last:

This 1NBIX.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. 1NBIX.MI Profitability Analysis

1.1 Basic Checks

  • In the past year 1NBIX was profitable.
  • In the past year 1NBIX had a positive cash flow from operations.
  • 1NBIX had positive earnings in each of the past 5 years.
  • In the past 5 years 1NBIX always reported a positive cash flow from operatings.
1NBIX.MI Yearly Net Income VS EBIT VS OCF VS FCF1NBIX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • With an excellent Return On Assets value of 10.33%, 1NBIX belongs to the best of the industry, outperforming 86.08% of the companies in the same industry.
  • 1NBIX has a better Return On Equity (14.71%) than 86.08% of its industry peers.
  • 1NBIX has a Return On Invested Capital of 11.30%. This is amongst the best in the industry. 1NBIX outperforms 86.08% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for 1NBIX is in line with the industry average of 11.59%.
Industry RankSector Rank
ROA 10.33%
ROE 14.71%
ROIC 11.3%
ROA(3y)9.06%
ROA(5y)7.61%
ROE(3y)13.03%
ROE(5y)10.93%
ROIC(3y)11.44%
ROIC(5y)10.33%
1NBIX.MI Yearly ROA, ROE, ROIC1NBIX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • The Profit Margin of 1NBIX (16.73%) is better than 78.48% of its industry peers.
  • 1NBIX's Profit Margin has declined in the last couple of years.
  • The Operating Margin of 1NBIX (22.25%) is better than 79.75% of its industry peers.
  • In the last couple of years the Operating Margin of 1NBIX has declined.
  • With an excellent Gross Margin value of 98.18%, 1NBIX belongs to the best of the industry, outperforming 96.20% of the companies in the same industry.
  • In the last couple of years the Gross Margin of 1NBIX has remained more or less at the same level.
Industry RankSector Rank
OM 22.25%
PM (TTM) 16.73%
GM 98.18%
OM growth 3Y9.73%
OM growth 5Y-6.6%
PM growth 3Y17.26%
PM growth 5Y-15.55%
GM growth 3Y-0.09%
GM growth 5Y-0.17%
1NBIX.MI Yearly Profit, Operating, Gross Margins1NBIX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. 1NBIX.MI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1NBIX is creating some value.
  • Compared to 1 year ago, 1NBIX has more shares outstanding
  • Compared to 5 years ago, 1NBIX has more shares outstanding
  • There is no outstanding debt for 1NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1NBIX.MI Yearly Shares Outstanding1NBIX.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
1NBIX.MI Yearly Total Debt VS Total Assets1NBIX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • An Altman-Z score of 7.45 indicates that 1NBIX is not in any danger for bankruptcy at the moment.
  • 1NBIX has a better Altman-Z score (7.45) than 78.48% of its industry peers.
  • There is no outstanding debt for 1NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.45
ROIC/WACC1.23
WACC9.19%
1NBIX.MI Yearly LT Debt VS Equity VS FCF1NBIX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • 1NBIX has a Current Ratio of 3.39. This indicates that 1NBIX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.39, 1NBIX is in the better half of the industry, outperforming 67.09% of the companies in the same industry.
  • 1NBIX has a Quick Ratio of 3.30. This indicates that 1NBIX is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 3.30, 1NBIX is doing good in the industry, outperforming 68.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 3.3
1NBIX.MI Yearly Current Assets VS Current Liabilites1NBIX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

9

3. 1NBIX.MI Growth Analysis

3.1 Past

  • 1NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.64%, which is quite impressive.
  • 1NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 29.09% yearly.
  • The Revenue has grown by 21.45% in the past year. This is a very strong growth!
  • The Revenue has been growing by 22.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)41.64%
EPS 3Y44.95%
EPS 5Y29.09%
EPS Q2Q%48%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y24.32%
Revenue growth 5Y22.29%
Sales Q2Q%28.33%

3.2 Future

  • The Earnings Per Share is expected to grow by 26.83% on average over the next years. This is a very strong growth
  • 1NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.12% yearly.
EPS Next Y32.86%
EPS Next 2Y33.83%
EPS Next 3Y32.11%
EPS Next 5Y26.83%
Revenue Next Year21.05%
Revenue Next 2Y15.58%
Revenue Next 3Y13.87%
Revenue Next 5Y10.12%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
1NBIX.MI Yearly Revenue VS Estimates1NBIX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
1NBIX.MI Yearly EPS VS Estimates1NBIX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

6

4. 1NBIX.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 28.39 indicates a quite expensive valuation of 1NBIX.
  • 1NBIX's Price/Earnings ratio is a bit cheaper when compared to the industry. 1NBIX is cheaper than 78.48% of the companies in the same industry.
  • 1NBIX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.91.
  • Based on the Price/Forward Earnings ratio of 21.37, the valuation of 1NBIX can be described as rather expensive.
  • Based on the Price/Forward Earnings ratio, 1NBIX is valued cheaply inside the industry as 84.81% of the companies are valued more expensively.
  • 1NBIX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.99, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 28.39
Fwd PE 21.37
1NBIX.MI Price Earnings VS Forward Price Earnings1NBIX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • 1NBIX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. 1NBIX is cheaper than 78.48% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, 1NBIX is valued cheaply inside the industry as 92.41% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.74
EV/EBITDA 16.55
1NBIX.MI Per share data1NBIX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • 1NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • 1NBIX has a very decent profitability rating, which may justify a higher PE ratio.
  • 1NBIX's earnings are expected to grow with 32.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.86
PEG (5Y)0.98
EPS Next 2Y33.83%
EPS Next 3Y32.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1NBIX.MI Dividend Analysis

5.1 Amount

  • No dividends for 1NBIX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1NBIX.MI Fundamentals: All Metrics, Ratios and Statistics

NEUROCRINE BIOSCIENCES INC

BIT:1NBIX (3/30/2026, 7:00:00 PM)

113

+1.45 (+1.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)05-06
Inst Owners100.45%
Inst Owner ChangeN/A
Ins Owners1.11%
Ins Owner ChangeN/A
Market Cap11.34B
Revenue(TTM)2.86B
Net Income(TTM)478.60M
Analysts84.44
Price Target152.97 (35.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-22.89%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-18.85%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)2
Avg EPS beat(8)-28.82%
EPS beat(12)4
Avg EPS beat(12)-75.12%
EPS beat(16)4
Avg EPS beat(16)-70.76%
Revenue beat(2)1
Avg Revenue beat(2)2.05%
Min Revenue beat(2)-0.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.81%
Min Revenue beat(4)-0.28%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.41%
Revenue beat(12)6
Avg Revenue beat(12)1.05%
Revenue beat(16)9
Avg Revenue beat(16)1.31%
PT rev (1m)-1.35%
PT rev (3m)-1.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-17.29%
EPS NY rev (1m)1.33%
EPS NY rev (3m)-14.07%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.83%
Valuation
Industry RankSector Rank
PE 28.39
Fwd PE 21.37
P/S 4.64
P/FCF 17.74
P/OCF 16.97
P/B 4.08
P/tB 4.08
EV/EBITDA 16.55
EPS(TTM)3.98
EY3.52%
EPS(NY)5.29
Fwd EY4.68%
FCF(TTM)6.37
FCFY5.64%
OCF(TTM)6.66
OCFY5.89%
SpS24.34
BVpS27.68
TBVpS27.68
PEG (NY)0.86
PEG (5Y)0.98
Graham Number49.7857 (-55.94%)
Profitability
Industry RankSector Rank
ROA 10.33%
ROE 14.71%
ROCE 16.37%
ROIC 11.3%
ROICexc 18.25%
ROICexgc 18.25%
OM 22.25%
PM (TTM) 16.73%
GM 98.18%
FCFM 26.17%
ROA(3y)9.06%
ROA(5y)7.61%
ROE(3y)13.03%
ROE(5y)10.93%
ROIC(3y)11.44%
ROIC(5y)10.33%
ROICexc(3y)28.05%
ROICexc(5y)23.52%
ROICexgc(3y)28.9%
ROICexgc(5y)24.22%
ROCE(3y)16.58%
ROCE(5y)14.96%
ROICexgc growth 3Y-5.34%
ROICexgc growth 5Y-9.62%
ROICexc growth 3Y-3.9%
ROICexc growth 5Y-9.62%
OM growth 3Y9.73%
OM growth 5Y-6.6%
PM growth 3Y17.26%
PM growth 5Y-15.55%
GM growth 3Y-0.09%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 112.96%
Cap/Sales 1.19%
Interest Coverage 250
Cash Conversion 117.42%
Profit Quality 156.44%
Current Ratio 3.39
Quick Ratio 3.3
Altman-Z 7.45
F-Score6
WACC9.19%
ROIC/WACC1.23
Cap/Depr(3y)128.93%
Cap/Depr(5y)141.45%
Cap/Sales(3y)1.44%
Cap/Sales(5y)1.5%
Profit Quality(3y)154.84%
Profit Quality(5y)186.73%
High Growth Momentum
Growth
EPS 1Y (TTM)41.64%
EPS 3Y44.95%
EPS 5Y29.09%
EPS Q2Q%48%
EPS Next Y32.86%
EPS Next 2Y33.83%
EPS Next 3Y32.11%
EPS Next 5Y26.83%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y24.32%
Revenue growth 5Y22.29%
Sales Q2Q%28.33%
Revenue Next Year21.05%
Revenue Next 2Y15.58%
Revenue Next 3Y13.87%
Revenue Next 5Y10.12%
EBIT growth 1Y9.18%
EBIT growth 3Y36.42%
EBIT growth 5Y14.21%
EBIT Next Year10.97%
EBIT Next 3Y23.29%
EBIT Next 5Y18.73%
FCF growth 1Y34.37%
FCF growth 3Y32.36%
FCF growth 5Y28.04%
OCF growth 1Y31.46%
OCF growth 3Y32.12%
OCF growth 5Y27.92%

NEUROCRINE BIOSCIENCES INC / 1NBIX.MI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NEUROCRINE BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 7 / 10 to 1NBIX.MI.


What is the valuation status for 1NBIX stock?

ChartMill assigns a valuation rating of 6 / 10 to NEUROCRINE BIOSCIENCES INC (1NBIX.MI). This can be considered as Fairly Valued.


Can you provide the profitability details for NEUROCRINE BIOSCIENCES INC?

NEUROCRINE BIOSCIENCES INC (1NBIX.MI) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for 1NBIX stock?

The Price/Earnings (PE) ratio for NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is 28.39 and the Price/Book (PB) ratio is 4.08.


What is the earnings growth outlook for NEUROCRINE BIOSCIENCES INC?

The Earnings per Share (EPS) of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is expected to grow by 32.86% in the next year.